滚动资讯
Endpoints NewsDid Eli Lilly just strike another gold mine?Endpoints NewsWhat’s familiar in health tech’s Q1 funding totalsEndpoints NewsStudy suggests $35 monthly insulin cap has increased patient accessPromega BlogNew Study Suggests Cancer Research Has an Age ProblemEndpoints NewsWhite House adds AbbVie's Humira to TrumpRx alongside cheaper biosimilarsBioPharma DiveTerns rebuffed a higher bid before selling to MerckFierceBiotechLilly pays AC Immune $12.5M to expand Alzheimer’s collab as asset draws closer to clinicFierceBiotechLongtime Hologic CEO Steve MacMillan to retire as $18.3B deal closesFierceBiotechOwlet CEO exits suddenly, co-founder returns to the nestFierceBiotechE2 lands $80M series C for next gen thrombectomy treatmentFierceBiotechCRO Fortrea launches AI-powered solution to improve trial efficiencyBioWorldAppointments and advancements for April 7, 2026
Endpoints News 2026年2月18日

礼来Zepbound与Taltz联合疗法公布银屑病与减重数据；诺华强化Rhapsido疗效结果。

礼来Zepbound与Taltz联合疗法公布银屑病与减重数据；诺华强化Rhapsido疗效结果。

原文
暂时没有全文，请查看原始来源。

目录

59 全部